Index -
P/E -
EPS (ttm) -0.78
Insider Own 30.72%
Shs Outstand 36.14M
Perf Week -9.40%
Market Cap 45.44M
Forward P/E -
EPS next Y -
Insider Trans 1.30%
Shs Float 29.70M
Perf Month -20.90%
Income -28.02M
PEG -
EPS next Q -
Inst Own 16.92%
Short Float 6.27%
Perf Quarter -5.36%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans -17.85%
Short Ratio 26.25
Perf Half Y -9.40%
Book/sh 2.29
P/B 0.46
EPS next Y -
ROA -28.72%
Short Interest 1.86M
Perf Year -29.80%
Cash/sh 1.94
P/C 0.55
EPS next 5Y 18.30%
ROE -29.87%
52W Range 0.84 - 1.93
Perf YTD 0.95%
Dividend Est. -
P/FCF -
EPS past 5Y -27.61%
ROI -33.71%
52W High -45.08%
Beta 1.26
Dividend TTM -
Quick Ratio 37.80
Sales past 5Y 0.00%
Gross Margin -
52W Low 26.19%
ATR (14) 0.09
Dividend Ex-Date -
Current Ratio 37.80
EPS Y/Y TTM 65.09%
Oper. Margin 0.00%
RSI (14) 34.06
Volatility 6.96% 7.64%
Employees 21
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 3.00
Target Price 12.00
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 33.32%
Payout -
Rel Volume 0.73
Prev Close 1.13
Sales Surprise -
EPS Surprise -81.95%
Sales Q/Q -
Earnings -
Avg Volume 70.98K
Price 1.06
SMA20 -10.57%
SMA50 -15.58%
SMA200 -12.08%
Trades
Volume 51,794
Change -6.19%
Feb-22-24 07:00AM
Feb-15-24 07:00AM
Feb-07-24 04:05PM
Jan-04-24 04:05PM
Dec-04-23 07:21AM
07:00AM
Loading…
Oct-23-23 07:00AM
Sep-28-23 04:05PM
Sep-06-23 07:00AM
Aug-15-23 10:20AM
Aug-10-23 04:05PM
Jul-24-23 07:00AM
Jul-13-23 08:00AM
Jun-06-23 08:00AM
Apr-11-23 07:00AM
Apr-06-23 04:05PM
04:05PM
Loading…
Apr-05-23 04:05PM
Mar-22-23 05:00AM
Mar-21-23 08:00AM
Jan-30-23 04:05PM
Jan-27-23 08:00AM
Nov-21-22 09:09AM
Sep-16-22 08:00AM
Sep-12-22 08:00AM
Aug-30-22 04:05PM
Aug-25-22 04:05PM
Aug-04-22 08:00AM
Aug-01-22 08:00AM
Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. Its pipeline consists of COR388, COR588, COR788, COR822, and Coronavirus 3CL protease inhibitor. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Thye Dirk CHIEF EXECUTIVE OFFICER Jan 16 '24 Option Exercise 0.79 240,530 190,791 689,441 Jan 17 04:48 PM Lamond David Director Dec 14 '23 Buy 1.04 22,627 23,532 2,347,545 Dec 14 06:21 PM Lamond David Director Dec 13 '23 Buy 1.00 22,627 22,627 2,324,918 Dec 14 06:21 PM Lamond David Director Dec 12 '23 Buy 1.02 22,327 22,774 2,302,291 Dec 14 06:21 PM Lamond David Director Dec 12 '23 Buy 1.00 300 300 2,279,964 Dec 14 06:21 PM Lamond David Director Dec 07 '23 Buy 1.01 19,123 19,314 2,279,664 Dec 07 06:30 PM Lamond David Director Dec 06 '23 Buy 1.02 19,123 19,505 2,260,541 Dec 07 06:30 PM Lamond David Director Dec 05 '23 Buy 1.01 19,123 19,314 2,241,418 Dec 07 06:30 PM Lamond David Director Dec 01 '23 Buy 0.94 14,378 13,515 2,222,295 Dec 01 01:38 PM Lamond David Director Nov 30 '23 Buy 0.90 14,378 12,940 2,207,917 Dec 01 01:38 PM Lamond David Director Nov 29 '23 Buy 0.98 14,378 14,090 2,193,539 Dec 01 01:38 PM Lamond David Director Aug 31 '23 Buy 1.32 41,026 54,154 2,179,161 Aug 31 06:42 PM Lamond David Director Aug 30 '23 Buy 1.31 41,026 53,744 2,138,135 Aug 31 06:42 PM Lamond David Director Aug 17 '23 Buy 1.29 24,766 31,948 2,097,109 Aug 17 06:08 PM Lamond David Director Aug 16 '23 Buy 1.29 117,348 151,379 2,072,343 Aug 17 06:08 PM Lamond David Director Aug 15 '23 Buy 1.32 107,886 142,410 1,954,995 Aug 17 06:08 PM Thye Dirk Chief Executive Officer Aug 10 '23 Buy 1.26 88,000 110,880 448,911 Aug 11 04:15 PM Thye Dirk Chief Executive Officer Aug 08 '23 Buy 1.24 80,000 99,200 360,911 Aug 09 06:23 PM Hannah Brendan Chief Business Officer Aug 08 '23 Buy 1.22 71,762 87,550 201,555 Aug 09 06:21 PM McLoughlin Margaret Director Aug 08 '23 Buy 1.23 8,000 9,840 8,000 Aug 09 06:18 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite